Vismodegib
Back to searchMolecule Structure
Scientific Name
Vismodegib
Description of the Drug
Vismodegib is a hedgehog pathway inhibitor used to treat patients with locally advanced or metastatic basal cell carcinoma.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08828
http://www.drugbank.ca/drugs/DB08828
Brand Name(s)
Erivedge
Company Owner(s)
Genentech Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Smoothened homolog | SINGLE PROTEIN | INHIBITOR | CHEMBL5971 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL302587 | |
Human Metabolome Database | HMDB0259838 | |
DrugBank | DB08828 | |
PubChem: Thomson Pharma | 49701104 | |
PubChem | 24776445 | |
Mcule | MCULE-6680076172 | |
LINCS | LSM-45691 | |
Nikkaji | J2.711.865H | |
PDBe | VIS | |
BindingDB | 50249522 | |
EPA CompTox Dashboard | DTXSID40236689 | |
DrugCentral | 4227 | |
ChemicalBook | CB52500590 | |
Guide to Pharmacology | 6975 | |
rxnorm | VISMODEGIB | ERIVEDGE |
PubChem: Drugs of the Future | 99431642 | |
ChEBI | 66903 | |
ZINC | ZINC000040899447 |